< Back to topics
> Cover Page, Authors, Institutions
> Purpose/Objective
> Materials/Methods
> Results/Discussion
> Conclusions
> View tables/images/videos
> View abstract & virtual poster in original format
|
|
Materials/Methods:
236 men with T1-T2 prostate cancer had real-time Pd-103 seed implantation without supplement external beam irradiation from 1990- 2004. The mean PSA was 10.6 ng/ml (median 7.7, range 0.5-57). PSA was <10 in 148 (62.7%), 10-20 in 61 (25.9%) and >20 in 27 (11.4%). Gleason score (GS) 6 or less was present in 111 (47.3%), 7in 98 (40.7%) and 8-9 in 27 (12%). 123 (52.2%) had clinical stage < T2a, 78 (33.2%) T2b and 32 (13.6%) T2c. Low risk disease (PSA<10 and GS<7 and stage100- 120 Gy, and >120 Gy). All values were reported according to the NIST99 standards. Post-implant saturation prostate biopsies were performed a minimum of 2 years after completion of therapy in 99 (42%). Three groups were created for analysis: group 1: PSA <10, GS<7, stage<100 Gy; group 2: PSA 10-20, GS=7, stage T2b, risk=2 and dose >100-120 Gy; and Group 3: PSA>20, GS 8-9, stage=T2c, risk=3 and dose >120 Gy. bFFF was determined using the ASTRO definition. Survival function was calculated using Kaplan Meier and Cox regression. Proportions were tested by cross tabulations.
|
|
